Rajeev Vibhakar
Concepts (405)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medulloblastoma | 37 | 2024 | 196 | 9.340 |
Why?
| | Cerebellar Neoplasms | 27 | 2024 | 155 | 7.190 |
Why?
| | Glioma | 19 | 2025 | 397 | 3.770 |
Why?
| | Rhabdoid Tumor | 10 | 2025 | 99 | 3.560 |
Why?
| | Brain Neoplasms | 26 | 2025 | 1241 | 3.400 |
Why?
| | Gene Expression Regulation, Neoplastic | 26 | 2025 | 1402 | 2.760 |
Why?
| | Radiation Tolerance | 7 | 2022 | 98 | 2.440 |
Why?
| | Cell Cycle Proteins | 8 | 2022 | 614 | 2.200 |
Why?
| | Cell Line, Tumor | 35 | 2025 | 3420 | 1.700 |
Why?
| | Cell Proliferation | 26 | 2025 | 2482 | 1.700 |
Why?
| | SMARCB1 Protein | 3 | 2025 | 31 | 1.580 |
Why?
| | Teratoma | 5 | 2022 | 114 | 1.520 |
Why?
| | Ependymoma | 11 | 2025 | 168 | 1.490 |
Why?
| | Protein-Tyrosine Kinases | 4 | 2020 | 434 | 1.360 |
Why?
| | Proto-Oncogene Proteins c-myc | 5 | 2024 | 141 | 1.360 |
Why?
| | Nuclear Proteins | 10 | 2025 | 710 | 1.300 |
Why?
| | Pyrazoles | 7 | 2022 | 427 | 1.150 |
Why?
| | Apoptosis | 20 | 2025 | 2557 | 1.120 |
Why?
| | Proto-Oncogene Proteins | 4 | 2022 | 646 | 1.100 |
Why?
| | Biomarkers, Tumor | 9 | 2021 | 1279 | 0.990 |
Why?
| | Cyclin-Dependent Kinase 6 | 4 | 2020 | 42 | 0.940 |
Why?
| | Sirtuin 2 | 1 | 2025 | 25 | 0.940 |
Why?
| | Brain Stem Neoplasms | 4 | 2021 | 83 | 0.940 |
Why?
| | Pyrimidines | 8 | 2019 | 472 | 0.940 |
Why?
| | Molecular Targeted Therapy | 4 | 2021 | 414 | 0.940 |
Why?
| | Antineoplastic Agents | 10 | 2022 | 2145 | 0.890 |
Why?
| | Radiation-Sensitizing Agents | 2 | 2016 | 43 | 0.890 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2019 | 328 | 0.850 |
Why?
| | Neoplastic Stem Cells | 4 | 2025 | 398 | 0.820 |
Why?
| | Genes, myc | 3 | 2020 | 48 | 0.810 |
Why?
| | MicroRNAs | 5 | 2020 | 704 | 0.790 |
Why?
| | Pyrimidinones | 4 | 2020 | 114 | 0.790 |
Why?
| | Hedgehog Proteins | 7 | 2022 | 197 | 0.790 |
Why?
| | Cellular Senescence | 3 | 2019 | 188 | 0.780 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 66 | 0.730 |
Why?
| | Cell Cycle | 11 | 2017 | 604 | 0.730 |
Why?
| | Infratentorial Neoplasms | 4 | 2025 | 63 | 0.720 |
Why?
| | Receptor, trkC | 1 | 2021 | 11 | 0.720 |
Why?
| | Receptor, trkB | 1 | 2021 | 34 | 0.700 |
Why?
| | Anilides | 3 | 2019 | 73 | 0.700 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 68 | 0.680 |
Why?
| | DNA Repair | 2 | 2024 | 230 | 0.670 |
Why?
| | Gene Expression Profiling | 15 | 2024 | 1770 | 0.660 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 40 | 0.650 |
Why?
| | Central Nervous System Neoplasms | 4 | 2019 | 158 | 0.650 |
Why?
| | Humans | 91 | 2025 | 137514 | 0.620 |
Why?
| | Pteridines | 2 | 2016 | 20 | 0.610 |
Why?
| | Deoxycytidine | 1 | 2020 | 176 | 0.610 |
Why?
| | Cerebellum | 5 | 2022 | 225 | 0.600 |
Why?
| | Membrane Glycoproteins | 1 | 2021 | 501 | 0.580 |
Why?
| | Oligonucleotide Array Sequence Analysis | 10 | 2016 | 765 | 0.580 |
Why?
| | Xenograft Model Antitumor Assays | 8 | 2025 | 868 | 0.570 |
Why?
| | Transcription Factors | 6 | 2023 | 1717 | 0.560 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 531 | 0.560 |
Why?
| | Histones | 4 | 2020 | 641 | 0.550 |
Why?
| | Glioblastoma | 3 | 2023 | 344 | 0.550 |
Why?
| | Tumor Cells, Cultured | 8 | 2025 | 957 | 0.530 |
Why?
| | Mice | 22 | 2025 | 17843 | 0.530 |
Why?
| | Vinblastine | 1 | 2016 | 71 | 0.520 |
Why?
| | Blotting, Western | 8 | 2019 | 1227 | 0.520 |
Why?
| | RNA, Small Interfering | 4 | 2022 | 621 | 0.520 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 30 | 0.520 |
Why?
| | Radiation, Ionizing | 3 | 2022 | 81 | 0.510 |
Why?
| | Bilirubin | 1 | 2016 | 97 | 0.510 |
Why?
| | Mutation | 9 | 2025 | 3964 | 0.510 |
Why?
| | Vincristine | 1 | 2016 | 116 | 0.510 |
Why?
| | Chromatin | 5 | 2025 | 524 | 0.500 |
Why?
| | Cell Survival | 8 | 2019 | 1122 | 0.500 |
Why?
| | Transcriptome | 6 | 2025 | 974 | 0.480 |
Why?
| | Enzyme Inhibitors | 6 | 2020 | 845 | 0.470 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2016 | 137 | 0.470 |
Why?
| | Child | 32 | 2025 | 22037 | 0.470 |
Why?
| | Polycomb Repressive Complex 2 | 2 | 2012 | 66 | 0.460 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2025 | 227 | 0.450 |
Why?
| | Histone Deacetylase Inhibitors | 3 | 2023 | 211 | 0.430 |
Why?
| | Cell Differentiation | 7 | 2025 | 1979 | 0.430 |
Why?
| | RNA, Messenger | 7 | 2014 | 2838 | 0.420 |
Why?
| | Animals | 23 | 2025 | 37011 | 0.410 |
Why?
| | Repressor Proteins | 3 | 2022 | 425 | 0.380 |
Why?
| | Child, Preschool | 19 | 2025 | 11097 | 0.360 |
Why?
| | Piperazines | 3 | 2022 | 351 | 0.360 |
Why?
| | Tumor Microenvironment | 3 | 2025 | 682 | 0.350 |
Why?
| | Azepines | 3 | 2019 | 90 | 0.340 |
Why?
| | Prognosis | 9 | 2020 | 4031 | 0.340 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 974 | 0.340 |
Why?
| | Epigenesis, Genetic | 4 | 2021 | 660 | 0.340 |
Why?
| | Neoplasms, Neuroepithelial | 2 | 2020 | 17 | 0.330 |
Why?
| | Intracellular Space | 1 | 2010 | 69 | 0.330 |
Why?
| | NF-kappa B | 5 | 2025 | 694 | 0.330 |
Why?
| | Genes, Tumor Suppressor | 2 | 2007 | 86 | 0.330 |
Why?
| | Neoplasm Proteins | 2 | 2012 | 433 | 0.320 |
Why?
| | Reactive Oxygen Species | 2 | 2022 | 619 | 0.310 |
Why?
| | Cisplatin | 3 | 2016 | 318 | 0.310 |
Why?
| | Real-Time Polymerase Chain Reaction | 4 | 2014 | 344 | 0.300 |
Why?
| | Drug Screening Assays, Antitumor | 4 | 2021 | 196 | 0.300 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 1695 | 0.290 |
Why?
| | Chromosomes, Human, Pair 1 | 2 | 2019 | 73 | 0.290 |
Why?
| | Protein Kinase Inhibitors | 2 | 2014 | 920 | 0.290 |
Why?
| | Quinazolines | 2 | 2022 | 249 | 0.290 |
Why?
| | Signal Transduction | 10 | 2025 | 5096 | 0.280 |
Why?
| | B7 Antigens | 2 | 2020 | 14 | 0.270 |
Why?
| | Aurora Kinases | 3 | 2012 | 27 | 0.270 |
Why?
| | Mice, Nude | 3 | 2020 | 696 | 0.270 |
Why?
| | DNA-Binding Proteins | 3 | 2017 | 1507 | 0.260 |
Why?
| | Aurora Kinase A | 3 | 2012 | 56 | 0.260 |
Why?
| | Combined Modality Therapy | 6 | 2019 | 1241 | 0.260 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2025 | 538 | 0.250 |
Why?
| | Phagocytosis | 2 | 2025 | 379 | 0.250 |
Why?
| | Polycomb Repressive Complex 1 | 2 | 2020 | 51 | 0.250 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 3 | 2023 | 51 | 0.250 |
Why?
| | Single-Cell Analysis | 4 | 2022 | 309 | 0.250 |
Why?
| | Autophagy | 2 | 2019 | 282 | 0.240 |
Why?
| | 12E7 Antigen | 1 | 2025 | 10 | 0.240 |
Why?
| | Epigenomics | 3 | 2020 | 115 | 0.240 |
Why?
| | Triazoles | 2 | 2019 | 151 | 0.240 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2007 | 379 | 0.230 |
Why?
| | Ganglioglioma | 1 | 2025 | 35 | 0.230 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2022 | 1060 | 0.230 |
Why?
| | Gene Fusion | 1 | 2025 | 27 | 0.230 |
Why?
| | Bone Morphogenetic Proteins | 2 | 2019 | 135 | 0.230 |
Why?
| | Protein-Arginine N-Methyltransferases | 1 | 2025 | 27 | 0.230 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2005 | 99 | 0.230 |
Why?
| | Phenanthrenes | 1 | 2024 | 13 | 0.220 |
Why?
| | Female | 27 | 2025 | 73162 | 0.220 |
Why?
| | Diterpenes | 1 | 2024 | 31 | 0.220 |
Why?
| | Epoxy Compounds | 1 | 2024 | 33 | 0.220 |
Why?
| | Positive Transcriptional Elongation Factor B | 1 | 2024 | 29 | 0.220 |
Why?
| | Macrophage Activation | 1 | 2025 | 201 | 0.220 |
Why?
| | Gene Rearrangement | 1 | 2025 | 151 | 0.220 |
Why?
| | Abnormalities, Multiple | 1 | 2005 | 189 | 0.210 |
Why?
| | Survival Rate | 5 | 2020 | 1980 | 0.210 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2019 | 806 | 0.200 |
Why?
| | Metencephalon | 1 | 2022 | 1 | 0.200 |
Why?
| | Cell Lineage | 2 | 2022 | 346 | 0.200 |
Why?
| | Disease-Free Survival | 3 | 2016 | 690 | 0.190 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 45 | 0.190 |
Why?
| | von Willebrand Diseases | 1 | 2022 | 27 | 0.190 |
Why?
| | DNA Copy Number Variations | 4 | 2021 | 185 | 0.190 |
Why?
| | Spheroids, Cellular | 2 | 2012 | 76 | 0.190 |
Why?
| | Genome, Human | 3 | 2014 | 424 | 0.190 |
Why?
| | von Willebrand Factor | 1 | 2022 | 81 | 0.190 |
Why?
| | Radiation | 1 | 2021 | 24 | 0.180 |
Why?
| | Pyridines | 3 | 2019 | 508 | 0.180 |
Why?
| | Neural Stem Cells | 2 | 2012 | 157 | 0.170 |
Why?
| | Mice, Transgenic | 3 | 2021 | 2182 | 0.170 |
Why?
| | RNA, Long Noncoding | 2 | 2021 | 181 | 0.170 |
Why?
| | Macrophages | 2 | 2025 | 1548 | 0.170 |
Why?
| | Fatal Outcome | 1 | 2021 | 305 | 0.170 |
Why?
| | Receptor, EphB4 | 1 | 2020 | 37 | 0.170 |
Why?
| | Antigens, Surface | 2 | 1997 | 154 | 0.170 |
Why?
| | Ephrin-B2 | 1 | 2020 | 51 | 0.170 |
Why?
| | Colony-Forming Units Assay | 2 | 2012 | 91 | 0.170 |
Why?
| | Craniospinal Irradiation | 1 | 2019 | 5 | 0.160 |
Why?
| | Adolescent | 13 | 2025 | 21555 | 0.160 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 80 | 0.160 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 17 | 0.160 |
Why?
| | RNA, Small Nuclear | 1 | 2019 | 37 | 0.160 |
Why?
| | Karyopherins | 1 | 2019 | 18 | 0.160 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2019 | 215 | 0.160 |
Why?
| | Kaplan-Meier Estimate | 3 | 2017 | 892 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2017 | 2066 | 0.160 |
Why?
| | Benzamides | 3 | 2019 | 218 | 0.160 |
Why?
| | Male | 21 | 2025 | 67718 | 0.150 |
Why?
| | Proteins | 3 | 2021 | 1012 | 0.150 |
Why?
| | Cell Self Renewal | 1 | 2019 | 54 | 0.150 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2021 | 856 | 0.150 |
Why?
| | Phenotype | 3 | 2024 | 3205 | 0.150 |
Why?
| | Infant | 12 | 2021 | 9467 | 0.150 |
Why?
| | Base Sequence | 4 | 2012 | 2180 | 0.150 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1428 | 0.150 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 226 | 0.140 |
Why?
| | Neoplasms | 2 | 2025 | 2666 | 0.140 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2019 | 220 | 0.140 |
Why?
| | Everolimus | 1 | 2017 | 91 | 0.140 |
Why?
| | Genes, p16 | 1 | 2017 | 20 | 0.140 |
Why?
| | Sulfonamides | 2 | 2022 | 513 | 0.140 |
Why?
| | E2F Transcription Factors | 1 | 2017 | 60 | 0.140 |
Why?
| | Recombinational DNA Repair | 1 | 2017 | 16 | 0.140 |
Why?
| | Cohort Studies | 6 | 2021 | 5730 | 0.140 |
Why?
| | Phthalazines | 1 | 2017 | 45 | 0.130 |
Why?
| | Morpholines | 1 | 2017 | 126 | 0.130 |
Why?
| | DNA Damage | 2 | 2017 | 420 | 0.130 |
Why?
| | DNA Methylation | 4 | 2021 | 644 | 0.130 |
Why?
| | Cell Division | 2 | 2010 | 795 | 0.130 |
Why?
| | Chloroquine | 1 | 2017 | 52 | 0.130 |
Why?
| | Benzodiazepinones | 1 | 2016 | 17 | 0.130 |
Why?
| | Stem Cells | 1 | 2021 | 589 | 0.130 |
Why?
| | Up-Regulation | 2 | 2016 | 846 | 0.130 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2016 | 24 | 0.130 |
Why?
| | Chromosome Aberrations | 1 | 2017 | 157 | 0.130 |
Why?
| | Microarray Analysis | 2 | 2017 | 116 | 0.130 |
Why?
| | Electric Stimulation Therapy | 1 | 2017 | 81 | 0.130 |
Why?
| | Immunophenotyping | 1 | 2017 | 321 | 0.130 |
Why?
| | Urea | 1 | 2016 | 81 | 0.130 |
Why?
| | Neoplasm Invasiveness | 2 | 2020 | 510 | 0.130 |
Why?
| | Thiophenes | 1 | 2016 | 118 | 0.120 |
Why?
| | Lysine | 2 | 2020 | 297 | 0.120 |
Why?
| | Survival Analysis | 2 | 2010 | 1320 | 0.120 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2025 | 319 | 0.120 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2016 | 190 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 437 | 0.120 |
Why?
| | Mitosis | 1 | 2016 | 193 | 0.120 |
Why?
| | Tumor Suppressor Proteins | 1 | 2017 | 328 | 0.120 |
Why?
| | Cancer Survivors | 1 | 2019 | 280 | 0.110 |
Why?
| | Genomics | 3 | 2017 | 793 | 0.110 |
Why?
| | HeLa Cells | 1 | 2016 | 640 | 0.110 |
Why?
| | Promoter Regions, Genetic | 3 | 2017 | 1255 | 0.110 |
Why?
| | Lymphocyte Activation | 2 | 2002 | 1150 | 0.110 |
Why?
| | Retrospective Studies | 6 | 2025 | 15628 | 0.110 |
Why?
| | Indoles | 1 | 2017 | 415 | 0.100 |
Why?
| | STAT3 Transcription Factor | 1 | 2015 | 208 | 0.100 |
Why?
| | Brain | 2 | 2020 | 2831 | 0.100 |
Why?
| | Flow Cytometry | 2 | 2019 | 1185 | 0.100 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 812 | 0.100 |
Why?
| | Cell Movement | 2 | 2020 | 972 | 0.100 |
Why?
| | Precision Medicine | 1 | 2017 | 426 | 0.100 |
Why?
| | Cathepsin B | 1 | 2012 | 14 | 0.100 |
Why?
| | Phosphorylation | 4 | 2020 | 1762 | 0.100 |
Why?
| | Rapamycin-Insensitive Companion of mTOR Protein | 1 | 2012 | 28 | 0.100 |
Why?
| | Argonaute Proteins | 1 | 2012 | 27 | 0.100 |
Why?
| | Wnt Proteins | 1 | 2014 | 133 | 0.100 |
Why?
| | Genomic Structural Variation | 1 | 2012 | 12 | 0.100 |
Why?
| | Acetylcysteine | 1 | 2013 | 147 | 0.100 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2012 | 141 | 0.100 |
Why?
| | Immunoenzyme Techniques | 1 | 2012 | 219 | 0.100 |
Why?
| | Luciferases | 1 | 2012 | 151 | 0.100 |
Why?
| | Astrocytoma | 2 | 2025 | 128 | 0.100 |
Why?
| | 3' Untranslated Regions | 1 | 2012 | 145 | 0.090 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 2615 | 0.090 |
Why?
| | Colorado | 1 | 2022 | 4521 | 0.090 |
Why?
| | Quality of Life | 2 | 2023 | 2870 | 0.090 |
Why?
| | Carrier Proteins | 2 | 2012 | 770 | 0.090 |
Why?
| | Tubulin | 1 | 2012 | 141 | 0.090 |
Why?
| | Carcinogenesis | 2 | 2025 | 220 | 0.090 |
Why?
| | Telomerase | 1 | 2013 | 250 | 0.090 |
Why?
| | Acetylation | 1 | 2011 | 254 | 0.090 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2012 | 141 | 0.090 |
Why?
| | RNA Interference | 1 | 2012 | 464 | 0.090 |
Why?
| | Interleukin-6 | 1 | 2015 | 778 | 0.090 |
Why?
| | Adenosine | 1 | 2012 | 227 | 0.090 |
Why?
| | Acetaminophen | 1 | 2013 | 269 | 0.090 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2017 | 620 | 0.080 |
Why?
| | Radiosurgery | 1 | 2014 | 346 | 0.080 |
Why?
| | Aging | 1 | 2020 | 1866 | 0.080 |
Why?
| | Tyrosine | 2 | 2023 | 224 | 0.080 |
Why?
| | Ki-67 Antigen | 2 | 2022 | 112 | 0.080 |
Why?
| | Hydroxamic Acids | 2 | 2007 | 89 | 0.080 |
Why?
| | Superoxides | 1 | 2010 | 202 | 0.080 |
Why?
| | Neoplasm Grading | 2 | 2021 | 308 | 0.080 |
Why?
| | Disease Models, Animal | 1 | 2019 | 4295 | 0.080 |
Why?
| | Gene Silencing | 2 | 2007 | 195 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 1997 | 1999 | 0.070 |
Why?
| | Histone Demethylases | 2 | 2022 | 34 | 0.070 |
Why?
| | Kidney Neoplasms | 1 | 2013 | 400 | 0.070 |
Why?
| | Cluster Analysis | 3 | 2017 | 502 | 0.070 |
Why?
| | Down-Regulation | 1 | 2010 | 658 | 0.070 |
Why?
| | Syndrome | 2 | 2005 | 359 | 0.070 |
Why?
| | Nerve Tissue Proteins | 2 | 2012 | 599 | 0.070 |
Why?
| | Scrotum | 1 | 2006 | 27 | 0.060 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2005 | 21 | 0.060 |
Why?
| | Young Adult | 5 | 2021 | 13243 | 0.060 |
Why?
| | Premedication | 1 | 2005 | 44 | 0.060 |
Why?
| | Transplantation Chimera | 1 | 2005 | 54 | 0.060 |
Why?
| | Anemia, Aplastic | 1 | 2005 | 38 | 0.060 |
Why?
| | CD47 Antigen | 1 | 2025 | 38 | 0.060 |
Why?
| | Drug Synergism | 2 | 2017 | 379 | 0.060 |
Why?
| | Computer Simulation | 2 | 2021 | 986 | 0.060 |
Why?
| | Molecular Sequence Data | 2 | 2008 | 2901 | 0.060 |
Why?
| | Neuroblastoma | 1 | 2006 | 161 | 0.060 |
Why?
| | Tissue Fixation | 1 | 2025 | 36 | 0.060 |
Why?
| | RNA | 1 | 2012 | 924 | 0.060 |
Why?
| | Testicular Neoplasms | 1 | 2006 | 110 | 0.060 |
Why?
| | Paraffin Embedding | 1 | 2025 | 32 | 0.060 |
Why?
| | Neutropenia | 1 | 2005 | 146 | 0.060 |
Why?
| | Formaldehyde | 1 | 2025 | 62 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2012 | 3546 | 0.060 |
Why?
| | Transplantation Conditioning | 1 | 2005 | 170 | 0.060 |
Why?
| | Prodrugs | 1 | 2024 | 49 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2420 | 0.050 |
Why?
| | Chromosomes | 1 | 2024 | 108 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2024 | 10821 | 0.050 |
Why?
| | Graft vs Host Disease | 1 | 2005 | 249 | 0.050 |
Why?
| | Organophosphates | 1 | 2024 | 134 | 0.050 |
Why?
| | Fluorouracil | 1 | 2024 | 213 | 0.050 |
Why?
| | Core Binding Factor alpha Subunits | 1 | 2022 | 2 | 0.050 |
Why?
| | Otx Transcription Factors | 1 | 2022 | 13 | 0.050 |
Why?
| | Graft Survival | 1 | 2005 | 540 | 0.050 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2023 | 171 | 0.050 |
Why?
| | Weibel-Palade Bodies | 1 | 2022 | 6 | 0.050 |
Why?
| | fas Receptor | 1 | 2002 | 95 | 0.050 |
Why?
| | Lymphoproliferative Disorders | 1 | 2002 | 55 | 0.050 |
Why?
| | T-Box Domain Proteins | 1 | 2022 | 98 | 0.050 |
Why?
| | Gene Ontology | 1 | 2021 | 53 | 0.050 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2022 | 104 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 234 | 0.040 |
Why?
| | Genetic Heterogeneity | 1 | 2021 | 59 | 0.040 |
Why?
| | Antigens, CD | 3 | 2002 | 524 | 0.040 |
Why?
| | RNA Polymerase II | 1 | 2024 | 324 | 0.040 |
Why?
| | Muscle Proteins | 1 | 2022 | 229 | 0.040 |
Why?
| | Ifosfamide | 1 | 2020 | 37 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2023 | 455 | 0.040 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2022 | 228 | 0.040 |
Why?
| | Transcription Factor HES-1 | 1 | 2019 | 5 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5139 | 0.040 |
Why?
| | Smoothened Receptor | 1 | 2019 | 6 | 0.040 |
Why?
| | MyoD Protein | 1 | 2019 | 35 | 0.040 |
Why?
| | Gain of Function Mutation | 1 | 2019 | 36 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2020 | 251 | 0.040 |
Why?
| | RNA Splice Sites | 1 | 2019 | 45 | 0.040 |
Why?
| | Risk Factors | 3 | 2021 | 10356 | 0.040 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 1997 | 188 | 0.040 |
Why?
| | Aminopyridines | 1 | 2019 | 101 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 367 | 0.040 |
Why?
| | Adult | 5 | 2021 | 37821 | 0.040 |
Why?
| | Gene Regulatory Networks | 1 | 2021 | 308 | 0.040 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 1997 | 252 | 0.040 |
Why?
| | Autoimmune Diseases | 1 | 2002 | 459 | 0.040 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 601 | 0.040 |
Why?
| | RNA Splicing | 1 | 2019 | 268 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2002 | 720 | 0.040 |
Why?
| | Drug Approval | 1 | 2018 | 87 | 0.040 |
Why?
| | Receptors, HIV | 1 | 2017 | 24 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2024 | 1458 | 0.030 |
Why?
| | Consensus | 1 | 2021 | 685 | 0.030 |
Why?
| | Mucin-1 | 1 | 2017 | 21 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 62 | 0.030 |
Why?
| | Alternative Splicing | 1 | 2019 | 227 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2017 | 34 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2021 | 504 | 0.030 |
Why?
| | Tetradecanoylphorbol Acetate | 1 | 1997 | 151 | 0.030 |
Why?
| | DNA, Complementary | 1 | 1997 | 269 | 0.030 |
Why?
| | Transfection | 1 | 2019 | 948 | 0.030 |
Why?
| | Jurkat Cells | 1 | 1997 | 134 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 125 | 0.030 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2017 | 100 | 0.030 |
Why?
| | Global Health | 1 | 2019 | 386 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 327 | 0.030 |
Why?
| | Radiotherapy | 1 | 2017 | 201 | 0.030 |
Why?
| | Genetic Variation | 1 | 2021 | 986 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 379 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 363 | 0.030 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2015 | 86 | 0.030 |
Why?
| | Canada | 1 | 2016 | 421 | 0.030 |
Why?
| | Health Status | 1 | 2019 | 784 | 0.030 |
Why?
| | Zinc Finger Protein Gli2 | 1 | 2014 | 4 | 0.030 |
Why?
| | Cytogenetics | 1 | 2014 | 10 | 0.030 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 2014 | 21 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2014 | 57 | 0.030 |
Why?
| | Hematopoietic Stem Cells | 1 | 1997 | 398 | 0.030 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 2014 | 59 | 0.030 |
Why?
| | Myeloid Cells | 1 | 2015 | 146 | 0.030 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2014 | 66 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2013 | 71 | 0.030 |
Why?
| | Gene Expression | 2 | 2010 | 1505 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 581 | 0.030 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2013 | 184 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2017 | 1740 | 0.020 |
Why?
| | Middle Aged | 3 | 2021 | 33355 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2013 | 401 | 0.020 |
Why?
| | Gene Duplication | 1 | 2012 | 69 | 0.020 |
Why?
| | Monocytes | 1 | 2015 | 568 | 0.020 |
Why?
| | Methylation | 1 | 2012 | 237 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2015 | 514 | 0.020 |
Why?
| | Translocation, Genetic | 1 | 2012 | 107 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 1997 | 847 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 2016 | 3722 | 0.020 |
Why?
| | Inflammation | 1 | 2023 | 2837 | 0.020 |
Why?
| | Glutathione | 1 | 2013 | 358 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2014 | 1263 | 0.020 |
Why?
| | Genome | 1 | 2012 | 292 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5792 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 480 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3301 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2014 | 2039 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1920 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2755 | 0.020 |
Why?
| | Cytokines | 1 | 2015 | 2095 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5772 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2014 | 3292 | 0.020 |
Why?
| | Azacitidine | 1 | 2006 | 141 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2193 | 0.010 |
Why?
| | Risk Assessment | 1 | 2014 | 3439 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2681 | 0.010 |
Why?
| | Receptors, Interleukin-2 | 1 | 2002 | 66 | 0.010 |
Why?
| | Antigens, Differentiation, T-Lymphocyte | 1 | 2002 | 98 | 0.010 |
Why?
| | Lectins, C-Type | 1 | 2002 | 72 | 0.010 |
Why?
| | Cytoplasm | 1 | 2002 | 274 | 0.010 |
Why?
| | Interleukin-4 | 1 | 2002 | 217 | 0.010 |
Why?
| | Interleukin-2 | 1 | 2002 | 456 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2011 | 6059 | 0.010 |
Why?
| | T-Lymphocyte Subsets | 1 | 2002 | 425 | 0.010 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2002 | 392 | 0.010 |
Why?
| | Interferon-gamma | 1 | 2002 | 790 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1997 | 76 | 0.010 |
Why?
| | Chromosomes, Human, Pair 2 | 1 | 1997 | 29 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1997 | 155 | 0.010 |
Why?
| | Interleukin-7 | 1 | 1997 | 62 | 0.010 |
Why?
| | Regulatory Sequences, Nucleic Acid | 1 | 1997 | 92 | 0.010 |
Why?
| | Genes | 1 | 1997 | 230 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1997 | 387 | 0.010 |
Why?
| | Bone Marrow | 1 | 1997 | 286 | 0.010 |
Why?
| | Calcium | 1 | 2002 | 1233 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 1997 | 1271 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1997 | 2146 | 0.010 |
Why?
| | Cells, Cultured | 1 | 1997 | 4206 | 0.010 |
Why?
|
|
Vibhakar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|